Oracle Health and AstraZeneca signed a nonbinding agreement in late October to explore using artificial intelligence across clinical trial recruitment, safety monitoring, and evidence generation, with their first joint program focused on hypertension care and trial recruitment through a partnership with M42, a health system based in Abu Dhabi. The deal reflects a broader industry push to solve one of drug development’s most persistent and expensive bottlenecks: finding and enrolling the right patients fast enough to keep trials on schedule.
Why Patient Recruitment Is Such a Costly Problem
Clinical trial delays caused by slow patient enrollment cost the pharmaceutical industry billions of dollars annually, as every month a trial runs behind schedule pushes back a drug’s potential approval and revenue timeline while continuing to incur fixed trial costs. Historically, identifying eligible patients has relied heavily on manual chart review by clinical research coordinators sifting through electronic health records for patients matching complex, multi-criteria trial eligibility requirements — a slow, labor-intensive process prone to missing qualified candidates.
The Evidence That AI Actually Helps
Early results from similar efforts elsewhere in the industry suggest the approach can work. Ochsner Health reported a 41% increase in clinical trial screening capacity alongside roughly 75% less manual screening work after implementing an AI matching system, according to data presented at the HLTH health technology conference. Separately, Cleveland Clinic and Dyania Health won a 2026 Gartner Eye on Innovation Award for AI work that study teams say helped them enroll patients 40% faster on average after their Synapsis AI platform went enterprise-wide.
How the Technology Works
These systems typically use large language models to parse both structured and unstructured data in electronic health records — lab results, physician notes, imaging reports — against a trial’s detailed eligibility criteria, surfacing a ranked list of potentially eligible patients for human coordinators to review and contact, rather than requiring coordinators to manually screen every record in a health system’s database. That triage function is where most of the time savings come from, since coordinators still make final determinations and handle patient outreach themselves.
The Skeptical Case
Critics caution that vendor-reported efficiency statistics, including both the Ochsner and Cleveland Clinic figures, come from company or health-system announcements rather than independent peer-reviewed validation, making it difficult to assess how representative these results are across different trial types, patient populations, and disease areas. There are also ongoing concerns about whether AI matching systems could inadvertently introduce bias into recruitment, for instance by underrepresenting patients whose records are less complete or who receive care across fragmented, poorly-integrated health systems.
Why AstraZeneca and Oracle Specifically
AstraZeneca has been among the most aggressive pharmaceutical companies in pursuing AI partnerships across its drug development pipeline in 2026, while Oracle has pushed its health IT division further into AI-enabled clinical infrastructure following its 2022 acquisition of Cerner. The partnership gives Oracle a high-profile pharmaceutical validation point for its AI health platform ambitions, while giving AstraZeneca access to Oracle’s health data infrastructure across multiple geographies, including the Gulf region through the M42 partnership.
What’s Next
As a nonbinding agreement, the Oracle-AstraZeneca partnership still needs to translate into concrete pilot programs with measurable enrollment outcomes before its impact can be assessed. Industry watchers will be looking for independent, peer-reviewed studies on AI-assisted recruitment outcomes to emerge over the coming year, which would offer more rigorous evidence than the vendor-reported statistics currently driving enthusiasm for the approach.
Photo: Gustavo Fring / PEXELS via Pexels
